Bernstein analyst Lance Wilkes downgraded Agilon Health (AGL) to Market Perform from Outperform with a price target of $1.40, down from $4. The firm cites the company’s worse than expected margin pressure for the downgrade. Agilon’s margin challenges reduce its capital cushion and increases its cost of capital, which creates an uncertain growth outlook, the analyst tells investors in a research note. Bernstein does not see the company as representing a strategically valuable asset that could be attractive to buyers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
- Agilon Health price target lowered to $1.10 from $2.40 at Jefferies
- Agilon Health price target lowered to $1 from $5 at Baird
- Agilon Health’s Earnings Call: Challenges and Optimism
- Agilon Health Faces Uncertainty Amid RAF Challenges and Leadership Changes